Patents
Literature
14 results about "FGFR Inhibition" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Inhibition of fibroblastic growth factor receptor signaling pathway activity to prevent tumor growth.
Indazole compounds for the treatment of cancer
PCT designated stage expiredWO2025129014A1Organic active ingredientsOrganic chemistryDiseaseBiochemistry
Disclosed herein are compounds and methods of treating diseases and / or conditions associated with FGFR inhibition.
Owner:TYRA BIOSCIENCES INC
Compounds for FGFR inhibition
A compound having the following structure of Formula (IV):or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Compounds for FGFR inhibition
A compound having the following structure of Formula (IV):or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Compounds for FGFR inhibition
PCT designated stage expiredWO2025034912A9Organic active ingredientsOrganic chemistryDiseaseFGFR Inhibition
A compound having the following structure of Formula (IV): (IV) or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Compounds for FGFR inhibition
A compound having the following structure of Formula (IV):or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Compounds for FGFR inhibition
PCT designated stage expiredWO2025034912A2Organic active ingredientsOrganic chemistryDiseasePharmaceutical drug
A compound having the following structure of Formula (IV): (IV) or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Indazole compounds as kinase inhibitors
Disclosed herein are compounds and methods of treating diseases and / or conditions associated with FGFR inhibition.
Owner:TYRA BIOSCIENCES INC
Indazole compounds
Disclosed herein are compounds and methods of treating diseases and / or conditions associated with FGFR inhibition.
Owner:TYRA BIOSCIENCES INC
Compounds for fgfr inhibition
A compound having the structure of the following Formula (IV): (IV) or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Also described are pharmaceutical compositions comprising the compound and uses thereof in methods of treating diseases.
Owner:COGENT BIOSCIENCES
Compounds for FGFR inhibition
PCT designated stage expiredWO2025034912A3Organic active ingredientsOrganic chemistryDiseaseFGFR Inhibition
A compound having the following structure of Formula (IV): (IV) or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
Owner:COGENT BIOSCIENCES INC
Indazole compounds
Disclosed herein are compounds and methods for treating diseases and / or conditions associated with FGFR inhibition.
Owner:TYRA BIOSCIENCES INC
Indazole compounds
Disclosed herein are compounds and methods for treating diseases and / or conditions associated with FGFR inhibition.
Owner:TYRA BIOSCIENCES INC
